Adaptimmune Therapeutics Plc - ADAP STOCK NEWS

Adaptimmune Therapeutics (ADAP) announced its ongoing enrollment in the SPEARHEAD-1 trial, targeting ADP-A2M4 for synovial sarcoma. The company is set to initiate a trial for ADP-A2M4CD8 in gastroesophageal cancers in the first half of 2021. The MAGE-A4 target shows strong efficacy potential across multiple solid tumors. Adaptimmune aims to introduce five new autologous products and two allogeneic products by 2024. Financial guidance is updated, indicating funding through early 2023. A Virtual Investor Day is scheduled, showcasing strategic visions and growth plans.

Adaptimmune Therapeutics (Nasdaq: ADAP) presented positive data from the Phase 1 ADP-A2M4 trial for synovial sarcoma at the CTOS annual meeting. The trial showed a 28-week median duration of response and a 94% disease control rate among 16 patients. The company aims to complete recruitment for the pivotal SPEARHEAD-1 trial by Q1 2021, with a goal to commercialize ADP-A2M4 in 2022. Additional trials for gastroesophageal cancers are planned for H1 2021.

Adaptimmune Therapeutics, a leader in cancer cell therapy, will host a virtual Investor Day on November 20, 2020. The event, set for 8 AM EST / 1 PM GMT, aims to highlight the market potential of its SPEAR T-cell portfolio and discuss its early-stage pipeline beyond current autologous TCR T-cell products. Presentations will be made by the Senior Leadership Team and Dr. Dejka Araujo from MD Anderson Cancer Center. Interested parties can register here.

Adaptimmune Therapeutics (Nasdaq: ADAP) presented data from the Phase 1 SURPASS trial for ADP-A2M4CD8, a novel cancer immunotherapy, at the SITC Conference. Of six heavily pre-treated patients, two achieved confirmed partial responses, with tumor shrinkage observed in five. The company plans to initiate a Phase 2 trial targeting gastroesophageal cancers in the first half of 2021. Preliminary findings suggest ADP-A2M4CD8 may be more effective than earlier versions, with ongoing research into enhanced T-cell manufacturing processes.

Adaptimmune Therapeutics (Nasdaq: ADAP) reported Q3 2020 financial results, revealing revenue growth to $1.2 million, up from $0.2 million a year earlier, driven by collaborations with Astellas and GSK. The company confirmed financial guidance to be funded into 2022, with $78.5 million in cash and total liquidity of $399.9 million. Clinical updates include promising data from Phase 1 trials for liver cancer and synovial sarcoma. Recruitment for ongoing trials is recovering post-COVID-19, with a Phase 2 trial for gastroesophageal cancers expected in H1 2021.

Adaptimmune Therapeutics plc (Nasdaq:ADAP) will report its Q3 2020 financial results and provide a business update on November 5, 2020, before U.S. markets open. The company is recognized for its innovative cancer immunotherapy products, particularly its SPEAR® T-cell platform, engineered to target and eliminate cancer across various solid tumors. A teleconference and webcast will follow the results announcement at 8:00 a.m. EST.

Adaptimmune has announced the early release of the abstract detailing the initial safety and efficacy data from the SURPASS trial involving ADPA2M4CD8, a novel SPEAR T-cell therapy targeting MAGE-A4. The abstract reveals that as of July 16, 2020, five patients have been treated without any dose-limiting toxicities or serious adverse events. Notably, significant responses were observed in patients with esophagogastric junction and head and neck cancers, indicating promising antitumor activity. Full trial results will be presented at the upcoming SITC conference on November 11, 2020.

Adaptimmune Therapeutics presented data from its Phase 1 trial of ADP-A2AFP targeting alpha-fetoprotein (AFP) at the International Liver Congress. One out of four patients treated with five billion or more SPEAR T-cells achieved a complete response, demonstrating acceptable safety despite subsequent disease progression. Notably, a total of nine patients have been treated, with ongoing evaluations of the therapy's effectiveness. Results support further development of ADP-A2AFP for hepatocellular carcinoma (HCC), as the company continues patient enrollment in the expansion phase.

Adaptimmune Therapeutics (Nasdaq: ADAP) reported Q2 2020 financial results, noting significant progress with its ADP-A2M4 therapy for sarcoma. The company raised approximately $244 million through a public offering, ensuring funding into 2022. They received PRIME regulatory support from the EMA for ADP-A2M4 targeting synovial sarcoma and reported responses in multiple solid tumor types during ASCO. The net loss for Q2 was $29.9 million, an improvement over last year's loss of $41.1 million. The company plans to launch ADP-A2M4 in the US in 2022 and continues to advance its clinical trials.